Shire plc / Advanced BioHealing, Inc.

Diabetic Foot Ulcers

$3.0B US diabetic foot ulcer addressable market (slow-healing segment, ~2011)

Disease Overview

Diabetic foot ulcers are chronic non-healing wounds affecting roughly 6-8% of diabetic Medicare beneficiaries at any given time, with a 19-34% lifetime risk among people with diabetes. They are the leading cause of non-traumatic lower-extremity amputations, drive substantial Medicare spending, and resist standard wound care — making advanced biologic skin substitutes a high-need but commercially difficult segment.

Competitive Landscape

Dermagraft is a cryopreserved allogeneic neonatal dermal fibroblast scaffold first FDA-approved in 2001 for diabetic foot ulcers. At the time of Shire's May 2011 acquisition, the bioengineered skin substitute market was a duopoly: Dermagraft and Organogenesis's Apligraf (a bilayered keratinocyte-fibroblast living-cell product). Smith & Nephew's Oasis (porcine SIS) and KCI's negative-pressure wound therapy played in adjacent positions. Dermagraft held ~5% of an estimated $3B slow-healing DFU addressable market — small, but Shire framed the deal as the foundation of a new regenerative medicine business unit anchored on Vyvanse-style specialty cash flow. The deal then unraveled. A 2012 Phase 3 trial in venous leg ulcers failed, blocking label expansion. CMS reimbursement reforms in 2013-2014 cut Medicare payment for cellular skin substitutes, undermining the unit economics that had justified the price. By January 2014 Shire announced a $650M impairment charge and divested the business to Organogenesis, consolidating the duopoly and effectively ending Shire's regenerative medicine push. The deal is widely cited in pharma BD postmortems as a cautionary tale of buying into a single-product, reimbursement-fragile device franchise at a premium valuation.